Empfehlung
6,7
Stark Verkaufen
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,72% (Stand: 28.02.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
Stammdaten
Unternehmen
| Name | ARTIVION, INC. |
|---|---|
| Ticker | AORT |
| CIK | 0000784199 |
Branche
| SIC-Code | 3841 |
|---|---|
| Beschreibung | Surgical & Medical Instruments & Apparatus |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | ARTIVION, INC. |
Status
| Zuletzt geprüft | 2026-03-22 13:22:59.049439 |
|---|
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -8,962 | 38.00 | -340,556.00 | -109,6% | |
| 2026-03-04 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -8,962 | 38.00 | -340,556.00 | -109,6% | |
| 2026-03-03 | Mackin James P | Officer, President & CEO | Open Market Sale | -17,887 | 37.78 | -675,692.16 | -217,5% | |
| 2026-03-03 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -6,316 | 37.78 | -238,590.69 | -76,8% | |
| 2026-03-03 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -6,316 | 37.78 | -238,590.69 | -76,8% | |
| 2026-03-03 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -4,573 | 37.78 | -172,747.82 | -55,6% | |
| 2026-03-03 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -4,573 | 37.78 | -172,747.82 | -55,6% | |
| 2026-03-03 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2,149 | 37.78 | -81,179.76 | -26,1% | |
| 2026-03-03 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2,149 | 37.78 | -81,179.76 | -26,1% | |
| 2026-03-03 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -3,843 | 37.78 | -145,171.63 | -46,7% | |
| 2026-03-03 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -3,843 | 37.78 | -145,171.63 | -46,7% | |
| 2026-03-03 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -901 | 37.78 | -34,035.82 | -11,0% | |
| 2026-03-03 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -901 | 37.78 | -34,035.82 | -11,0% | |
| 2026-03-03 | Mackin James P | Officer, President & CEO | Open Market Sale | -17,887 | 37.78 | -675,692.16 | -217,5% | |
| 2026-03-02 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,513 | 38.02 | -57,531.67 | -18,5% | |
| 2026-03-02 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -641 | 38.02 | -24,373.96 | -7,8% | |
| 2026-03-02 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -641 | 38.02 | -24,373.96 | -7,8% | |
| 2026-03-02 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,513 | 38.02 | -57,531.67 | -18,5% | |
| 2026-03-02 | Mackin James P | Officer, President & CEO | Open Market Sale | -14,911 | 38.02 | -566,989.28 | -182,5% | |
| 2026-03-02 | Mackin James P | Officer, President & CEO | Open Market Sale | -14,911 | 38.02 | -566,989.28 | -182,5% | |
| 2026-03-02 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -2,183 | 38.02 | -83,008.36 | -26,7% | |
| 2026-03-02 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -2,183 | 38.02 | -83,008.36 | -26,7% | |
| 2026-03-02 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -5,178 | 38.02 | -196,892.93 | -63,4% | |
| 2026-03-02 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -5,178 | 38.02 | -196,892.93 | -63,4% | |
| 2026-03-02 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -2,784 | 38.02 | -105,861.32 | -34,1% | |
| 2026-03-02 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -2,784 | 38.02 | -105,861.32 | -34,1% | |
| 2026-02-24 | Mackin James P | Officer, President & CEO | Open Market Sale | -13,936 | 35.69 | -497,417.65 | -160,1% | |
| 2026-02-24 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -1,668 | 35.69 | -59,535.92 | -19,2% | |
| 2026-02-24 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -4,485 | 35.69 | -160,083.11 | -51,5% | |
| 2026-02-24 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -4,485 | 35.69 | -160,083.11 | -51,5% | |
| 2026-02-24 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,259 | 35.69 | -44,937.49 | -14,5% | |
| 2026-02-24 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -830 | 35.69 | -29,625.19 | -9,5% | |
| 2026-02-24 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -2,075 | 35.69 | -74,062.98 | -23,8% | |
| 2026-02-24 | Mackin James P | Officer, President & CEO | Open Market Sale | -13,936 | 35.69 | -497,417.65 | -160,1% | |
| 2026-02-24 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -830 | 35.69 | -29,625.19 | -9,5% | |
| 2026-02-24 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,259 | 35.69 | -44,937.49 | -14,5% | |
| 2026-02-24 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -2,075 | 35.69 | -74,062.98 | -23,8% | |
| 2026-02-24 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -1,668 | 35.69 | -59,535.92 | -19,2% | |
| 2026-02-23 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -4,981 | 37.59 | -187,225.83 | -60,3% | |
| 2026-02-23 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -4,981 | 37.59 | -187,225.83 | -60,3% | |
| 2026-02-23 | Mackin James P | Officer, President & CEO | Open Market Sale | -20,962 | 37.59 | -787,919.66 | -253,6% | |
| 2026-02-23 | Mackin James P | Officer, President & CEO | Open Market Sale | -20,962 | 37.59 | -787,919.66 | -253,6% | |
| 2026-02-23 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -3,773 | 37.59 | -141,819.52 | -45,6% | |
| 2026-02-23 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -3,773 | 37.59 | -141,819.52 | -45,6% | |
| 2026-02-23 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -3,079 | 37.59 | -115,733.45 | -37,2% | |
| 2026-02-23 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -3,079 | 37.59 | -115,733.45 | -37,2% | |
| 2026-02-23 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2,423 | 37.59 | -91,075.72 | -29,3% | |
| 2026-02-23 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -1,731 | 37.59 | -65,064.83 | -20,9% | |
| 2026-02-23 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2,423 | 37.59 | -91,075.72 | -29,3% | |
| 2026-02-23 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -1,731 | 37.59 | -65,064.83 | -20,9% | |
| 2025-12-15 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -5,000 | 45.11 | -225,550.00 | -72,6% | |
| 2025-12-15 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -5,000 | 45.11 | -225,550.00 | -72,6% | |
| 2025-12-08 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -4,572 | 44.42 | -203,083.67 | -65,4% | |
| 2025-12-08 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -4,572 | 44.42 | -203,083.67 | -65,4% | |
| 2025-12-03 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -2,048 | 45.30 | -92,774.40 | -29,9% | |
| 2025-12-03 | Mackin James P | Officer, President & CEO | Open Market Sale | -30,921 | 45.46 | -1,405,699.58 | -452,4% | |
| 2025-12-03 | Mackin James P | Officer, President & CEO | Open Market Sale | -30,921 | 45.46 | -1,405,699.58 | -452,4% | |
| 2025-12-03 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -5,267 | 45.30 | -238,595.10 | -76,8% | |
| 2025-12-03 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -2,048 | 45.30 | -92,774.40 | -29,9% | |
| 2025-12-03 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -5,267 | 45.30 | -238,595.10 | -76,8% | |
| 2025-12-02 | Mackin James P | Officer, President & CEO | Open Market Sale | -30,921 | 45.56 | -1,408,729.84 | -453,4% | |
| 2025-12-02 | Mackin James P | Officer, President & CEO | Open Market Sale | -30,921 | 45.56 | -1,408,729.84 | -453,4% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -8,370 | 45.35 | -379,537.65 | -122,1% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -5,715 | 45.35 | -259,152.39 | -83,4% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -14,586 | 44.92 | -655,188.53 | -210,9% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -8,370 | 45.35 | -379,537.65 | -122,1% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -18,705 | 44.91 | -840,041.55 | -270,4% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -5,715 | 45.35 | -259,152.39 | -83,4% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -14,586 | 44.92 | -655,188.53 | -210,9% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -18,705 | 44.91 | -840,041.55 | -270,4% | |
| 2025-11-20 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2,033 | 44.32 | -90,092.40 | -29,0% | |
| 2025-11-20 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -11,888 | 44.14 | -524,736.32 | -168,9% | |
| 2025-11-20 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2,033 | 44.32 | -90,092.40 | -29,0% | |
| 2025-11-20 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,355 | 44.28 | -59,996.69 | -19,3% | |
| 2025-11-20 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -11,888 | 44.14 | -524,736.32 | -168,9% | |
| 2025-11-20 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,355 | 44.28 | -59,996.69 | -19,3% | |
| 2025-11-18 | Hoff Elizabeth A | Director | Open Market Sale | -4,200 | 45.10 | -189,411.60 | -61,0% | |
| 2025-11-18 | Hoff Elizabeth A | Director | Open Market Sale | -4,200 | 45.10 | -189,411.60 | -61,0% | |
| 2025-11-17 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -6,000 | 45.73 | -274,380.00 | -88,3% | |
| 2025-11-17 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -6,394 | 45.17 | -288,816.98 | -93,0% | |
| 2025-11-17 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -6,000 | 45.73 | -274,380.00 | -88,3% | |
| 2025-11-17 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -6,394 | 45.17 | -288,816.98 | -93,0% | |
| 2025-11-17 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -6,394 | 45.17 | -288,816.98 | -93,0% | |
| 2025-11-17 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -6,394 | 45.17 | -288,816.98 | -93,0% | |
| 2025-11-14 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -6,393 | 44.67 | -285,575.31 | -91,9% | |
| 2025-11-14 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -6,393 | 45.00 | -287,685.00 | -92,6% | |
| 2025-11-14 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -6,393 | 44.67 | -285,575.31 | -91,9% | |
| 2025-11-14 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -6,393 | 45.00 | -287,685.00 | -92,6% | |
| 2025-11-13 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -3,482 | 45.86 | -159,677.56 | -51,4% | |
| 2025-11-13 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -5,761 | 45.86 | -264,187.94 | -85,0% | |
| 2025-11-13 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -5,761 | 45.86 | -264,187.94 | -85,0% | |
| 2025-11-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -4,993 | 45.86 | -228,968.99 | -73,7% | |
| 2025-11-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -4,993 | 45.86 | -228,968.99 | -73,7% | |
| 2025-11-13 | Mackin James P | Officer, President & CEO | Open Market Sale | -34,210 | 45.86 | -1,568,802.18 | -504,9% | |
| 2025-11-13 | Mackin James P | Officer, President & CEO | Open Market Sale | -34,210 | 45.86 | -1,568,802.18 | -504,9% | |
| 2025-11-13 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -6,563 | 45.86 | -300,966.05 | -96,9% | |
| 2025-11-13 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -6,563 | 45.86 | -300,966.05 | -96,9% | |
| 2025-11-13 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -3,482 | 45.86 | -159,677.56 | -51,4% | |
| 2025-11-11 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -10,000 | 46.18 | -461,800.00 | -148,6% | |
| 2025-11-10 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2,566 | 44.62 | -114,492.35 | -36,8% | |
| 2025-11-10 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -1,789 | 44.62 | -79,823.39 | -25,7% | |
| 2025-11-10 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -1,789 | 44.62 | -79,823.39 | -25,7% | |
| 2025-11-10 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -3,373 | 44.62 | -150,499.89 | -48,4% | |
| 2025-11-10 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -3,373 | 44.62 | -150,499.89 | -48,4% | |
| 2025-11-10 | Mackin James P | Officer, President & CEO | Open Market Sale | -17,580 | 44.62 | -784,402.02 | -252,4% | |
| 2025-11-10 | Mackin James P | Officer, President & CEO | Open Market Sale | -17,580 | 44.62 | -784,402.02 | -252,4% | |
| 2025-11-10 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2,566 | 44.62 | -114,492.35 | -36,8% | |
| 2025-11-10 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -2,960 | 44.62 | -132,072.24 | -42,5% | |
| 2025-08-27 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -18,200 | 44.02 | -801,218.60 | -257,9% | |
| 2025-08-27 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -18,200 | 44.02 | -801,218.60 | -257,9% | |
| 2025-08-25 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -10,000 | 44.37 | -443,700.00 | -142,8% | |
| 2025-08-15 | Mackin James P | Officer, President & CEO | Open Market Sale | -12,500 | 42.32 | -528,987.50 | -170,2% | |
| 2025-08-15 | Mackin James P | Officer, President & CEO | Open Market Sale | -12,500 | 42.32 | -528,987.50 | -170,2% | |
| 2025-08-12 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -16,975 | 43.01 | -730,111.73 | -235,0% | |
| 2025-08-12 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -6,381 | 43.02 | -274,497.86 | -88,3% | |
| 2025-08-12 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -10,802 | 43.67 | -471,755.75 | -151,8% | |
| 2025-08-12 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -10,802 | 43.67 | -471,755.75 | -151,8% | |
| 2025-08-08 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -7,992 | 38.49 | -307,612.08 | -99,0% | |
| 2025-08-08 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -7,992 | 38.49 | -307,612.08 | -99,0% | |
| 2025-06-17 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -13,764 | 29.50 | -406,038.00 | -130,7% | |
| 2025-06-17 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -13,764 | 29.50 | -406,038.00 | -130,7% | |
| 2025-06-17 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,236 | 29.50 | -36,462.00 | -11,7% | |
| 2025-06-17 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,236 | 29.50 | -36,462.00 | -11,7% | |
| 2025-06-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -14,306 | 28.42 | -406,600.84 | -130,9% | |
| 2025-06-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -14,306 | 28.42 | -406,600.84 | -130,9% | |
| 2025-06-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,253 | 28.47 | -35,668.65 | -11,5% | |
| 2025-06-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -8,747 | 28.46 | -248,952.74 | -80,1% | |
| 2025-06-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,826 | 28.43 | -51,908.98 | -16,7% | |
| 2025-06-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,826 | 28.43 | -51,908.98 | -16,7% | |
| 2025-06-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,253 | 28.47 | -35,668.65 | -11,5% | |
| 2025-06-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -8,747 | 28.46 | -248,952.74 | -80,1% | |
| 2025-05-27 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -8,748 | 29.00 | -253,692.00 | -81,6% | |
| 2025-05-23 | SEMEDO ANTHONY B. | Director | Open Market Sale | -2,600 | 28.47 | -74,027.20 | -23,8% | |
| 2025-05-23 | SEMEDO ANTHONY B. | Director | Open Market Sale | -2,600 | 28.47 | -74,027.20 | -23,8% | |
| 2025-05-21 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -9,926 | 29.00 | -287,854.00 | -92,6% | |
| 2025-05-09 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -4,811 | 29.13 | -140,145.39 | -45,1% | |
| 2025-05-09 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -5,737 | 29.13 | -167,119.96 | -53,8% | |
| 2025-05-09 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -4,811 | 29.13 | -140,145.39 | -45,1% | |
| 2025-05-09 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -5,737 | 29.13 | -167,119.96 | -53,8% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.